These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1372339)

  • 21. Placental expression of substance P and vasoactive intestinal peptide: evidence for a local effect on hormone release.
    Marzioni D; Fiore G; Giordano A; Nabissi M; Florio P; Verdenelli F; Petraglia F; Castellucci M
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2378-83. PubMed ID: 15623814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
    Pozo D; Montilla ML; Guerrero JM; Calvo JR
    Eur J Pharmacol; 1997 Mar; 321(3):379-86. PubMed ID: 9085051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psoriasis and the nervous system.
    Pincelli C; Fantini F; Magnoni C; Giannetti A
    Acta Derm Venereol Suppl (Stockh); 1994; 186():60-1. PubMed ID: 8073840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of RANTES in psoriatic keratinocytes: a possible pathogenic mechanism for psoriasis.
    Raychaudhuri SP; Jiang WY; Farber EM; Schall TJ; Ruff MR; Pert CB
    Acta Derm Venereol; 1999 Jan; 79(1):9-11. PubMed ID: 10086850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors.
    Kakurai M; Fujita N; Murata S; Furukawa Y; Demitsu T; Nakagawa H
    J Invest Dermatol; 2001 May; 116(5):743-9. PubMed ID: 11348464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes.
    Granoth R; Fridkin M; Gozes I
    FEBS Lett; 2000 Jun; 475(2):78-83. PubMed ID: 10858492
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro.
    Leigh IM; Navsaria H; Purkis PE; McKay IA; Bowden PE; Riddle PN
    Br J Dermatol; 1995 Oct; 133(4):501-11. PubMed ID: 7577575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients.
    Mosimann BL; White MV; Hohman RJ; Goldrich MS; Kaulbach HC; Kaliner MA
    J Allergy Clin Immunol; 1993 Jul; 92(1 Pt 1):95-104. PubMed ID: 7687608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Occurrence of substance P, vasoactive intestinal peptide, and calcitonin gene-related peptide in dermographism and cold urticaria.
    Wallengren J; Möller H; Ekman R
    Arch Dermatol Res; 1987; 279(8):512-5. PubMed ID: 2449138
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of ribosomal protein S6 kinase in psoriatic lesions and cultured human keratinocytes by epidermal growth factor receptor ligands.
    Choi JH; O'Connor TP; Kang S; Voorhees JJ; Fisher GJ
    J Invest Dermatol; 1997 Jan; 108(1):98-102. PubMed ID: 8980296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A.
    Al-Daraji WI; Grant KR; Ryan K; Saxton A; Reynolds NJ
    J Invest Dermatol; 2002 May; 118(5):779-88. PubMed ID: 11982754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M; Robberecht P; Coy DH; Camus JC; De Neef P; Christophe J
    Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyperproliferation of normally quiescent keratinocytes in non-lesional psoriatic skin due to high calcium concentration (an organotypic culture model).
    Szabó AK; Bos JD; Das PK
    Acta Microbiol Immunol Hung; 2002; 49(1):129-40. PubMed ID: 12073819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vasoactive intestinal polypeptide in allergic contact dermatitis: an immunohistochemical and radioimmunoassay study.
    Lundeberg L; Nordlind K
    Arch Dermatol Res; 1999 Apr; 291(4):201-6. PubMed ID: 10335916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide specificity for stimulation of corticotropin secretion: activation of overlapping pathways by the vasoactive intestinal peptide family and corticotropin-releasing factor.
    Westendorf JM; Schonbrunn A
    Endocrinology; 1985 Jun; 116(6):2528-35. PubMed ID: 2859986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substance P and vasoactive intestinal peptide in bullous and inflammatory skin disease.
    Wallengren J; Ekman R; Möller H
    Acta Derm Venereol; 1986; 66(1):23-8. PubMed ID: 2424210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropeptides and general neuronal marker in psoriasis--an immunohistochemical study.
    Al'Abadie MS; Senior HJ; Bleehen SS; Gawkrodger DJ
    Clin Exp Dermatol; 1995 Sep; 20(5):384-9. PubMed ID: 8593714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Substance P levels are decreased in lesional skin of atopic dermatitis.
    Fantini F; Pincelli C; Romualdi P; Donatini A; Giannetti A
    Exp Dermatol; 1992 Oct; 1(3):127-8. PubMed ID: 1285408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasoactive intestinal peptide supports induced migration of human keratinocytes and their colonization of an artificial polyurethane matrix.
    Wollina U; Huschenbeck J; Knöll B; Sternberg B; Hipler UC
    Regul Pept; 1997 May; 70(1):29-36. PubMed ID: 9250579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M; Couvineau A; Rouyer-Fessard C
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.